Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06098235

Oriental Intervention for Enhanced Neurocognitive Health (Orient) Diet in Populations With High Risk of Stroke (ENDS)

This randomized controlled trial will enroll 160 individuals aged over 40 without dementia who are at high risk of stroke, collecting multi-modal MRI imaging, serum, and fecal samples to investigate the impact of the ORIENT diet on brain functional networks.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Second Affilated Hospital of Zhejiang University, School of Medicine

Hangzhou, Zhejiang, 310009, China

Location status: Recruiting

Location contact

Min Lou, PhD, MD

CONTACT

[email protected]

13958007213

About this study

Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) Diet in Populations with High Risk of Stroke is designed to test the impact of a 6-month intervention utilizing a culturally adapted version of the MIND diet, named as the ORIENT diet, on 160 participants (aged 40 years and above, and without dementia) with high risk of stroke (defined as having transient ischemic attack or having ≥ 3 stroke risk factors including hypertension, dyslipidemia, diabetes, atrial fibrillation or valvular heart disease, smoking history, obvious overweight or obesity, lack of exercise, family history of stroke). The ORIENT diet retains the core components of the DASH, Mediterranean, and MIND diets, but incorporates adjustments according to evidence derived from Asian prospective cohorts and Chinese dietary practices. Participants in the intervention group will receive the ORIENT diet intervention, while participants in the control group will receive standard low-sodium and low-fat dietary advice. The study's primary objective is to assess the impact of the ORIENT diet on the brain functional networks of individual with high risk of stroke. The investigation will explore potential mediators and modifiers of the intervention's effects by collecting various cardiovascular risk factors, serum samples, fecal samples, neuropsychological assessment results, and multi-modal magnetic resonance imaging at baseline, 6 months, and 2 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged ≥ 40 years
  • High risk of stroke (with ≥ 3 of 8 stroke risk factors, including hypertension, dyslipidemia, diabetes, atrial fibrillation or valvular heart disease, smoking history, obvious overweight or obesity, lack of exercise, family history of stroke, or with transient ischemic attack)
  • Written informed consent available
  • Willingness to complete all assessments and participate in follow-up
  • Adequate Visual and auditory acuity to undergo neuropsychological testing

Exclusion criteria

  • Nuts, berries, olive oil, or fish allergies
  • previously diagnosed dementia
  • Suspected dementia after clinical assessment by study physician at screening visit
  • Previous history of major head trauma and any intracranial surgery
  • Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions
  • Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement
  • Severe loss of vision, hearing, or communicative ability
  • Patients presenting a malignant disease with life expectancy < 3 years
  • Participation in an ongoing investigational drug study
  • Any MRI contraindications

Exit Criteria:

  • Not meet the inclusion criteria
  • For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator
  • Any adverse or serious adverse events during the study period judged by Investigator

Treatment and study plan

Usual Diet advice

Behavioral

The usual diet advice include recommendations in guidelines, such as reducing salt and fat intake.

ORIENT diet intervention

Behavioral

The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.

Primary outcomes

  1. Changes in brain functional network connectivity assessed by resting state functional magnetic resonance imaging (fMRI)

    Time frame: 6 months

    Primary Outcome

Secondary outcomes

  1. Changes in brain functional network efficiency assessed by resting state fMRI

    Time frame: 2 years

    long-term secondary outcome

  2. Changes in brain functional network activity intensity assessed by resting state fMRI

    Time frame: 2 years

    long-term secondary outcome

  3. Changes in brain functional network efficiency assessed by resting state fMRI

    Time frame: 5 years

    long-term secondary outcome

  4. Changes in brain functional network activity intensity assessed by resting state fMRI

    Time frame: 5 years

    long-term secondary outcome

  5. Changes in brain functional network efficiency assessed by resting state fMRI

    Time frame: 6 months

    short-term secondary outcome

  6. Changes in brain functional network activity intensity assessed by resting state fMRI

    Time frame: 6 months

    short-term secondary outcome

  7. Changes in brain functional network connectivity assessed by resting state fMRI

    Time frame: 2 years

    long-term secondary outcome

  8. Changes in brain functional network connectivity assessed by resting state fMRI

    Time frame: 5 years

    long-term secondary outcome

  9. Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)

    Time frame: 6 months

    short-term secondary outcome

  10. Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)

    Time frame: 2 years

    long-term secondary outcome

  11. Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)

    Time frame: 5 years

    long-term secondary outcome

  12. Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)

    Time frame: 6 months

    short-term secondary outcome

  13. Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)

    Time frame: 2 years

    long-term secondary outcome

  14. Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)

    Time frame: 5 years

    long-term secondary outcome

  15. Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)

    Time frame: 6 months

    short-term secondary outcome

  16. Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)

    Time frame: 2 years

    long-term secondary outcome

  17. Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)

    Time frame: 5 years

    long-term secondary outcome

  18. Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)

    Time frame: 6 months

    short-term secondary outcome

  19. Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)

    Time frame: 2 years

    long-term secondary outcome

  20. Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)

    Time frame: 5 years

    long-term secondary outcome

  21. Changes in white matter hyperintensity (WMH) assessed on MRI with T2-Fluid-Attenuated-Inversion-Recovery (FLAIR) sequence

    Time frame: 6 months

    short-term secondary outcome

  22. Changes in lacunes assessed on MRI with T2 FLAIR sequence

    Time frame: 6 months

    short-term secondary outcome

  23. Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence

    Time frame: 6 months

    short-term secondary outcome

  24. Changes in microbleeds assessed on MRI with Susceptibility Weighted Imaging (SWI) sequence sequence

    Time frame: 6 months

    short-term secondary outcome

  25. Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI

    Time frame: 6 months

    short-term secondary outcome

  26. Changes in white matter hyperintensity (WMH) assessed on MRI with T2 FLAIR sequence

    Time frame: 2 years

    long-term secondary outcome

  27. Changes in white matter hyperintensity (WMH) assessed on MRI with T2 FLAIR sequence

    Time frame: 5 years

    long-term secondary outcome

  28. Changes in lacunes assessed on MRI with T2 FLAIR sequence

    Time frame: 2 years

    long-term secondary outcome

  29. Changes in lacunes assessed on MRI with T2 FLAIR sequence

    Time frame: 5 years

    long-term secondary outcome

  30. Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence

    Time frame: 2 years

    long-term secondary outcome

  31. Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence

    Time frame: 5 years

    long-term secondary outcome

  32. Changes in microbleeds assessed on MRI with SWI sequence sequence

    Time frame: 2 years

    long-term secondary outcome

  33. Changes in microbleeds assessed on MRI with SWI sequence sequence

    Time frame: 5 years

    long-term secondary outcome

  34. Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI

    Time frame: 2 years

    long-term secondary outcome

  35. Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI

    Time frame: 5 years

    long-term secondary outcome

  36. Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)

    Time frame: 6 months

    short-term secondary outcome

  37. Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)

    Time frame: 2 years

    long-term secondary outcome

  38. Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)

    Time frame: 5 years

    long-term secondary outcome

  39. Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image

    Time frame: 6 months

    short-term secondary outcome

  40. Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image

    Time frame: 2 years

    long-term secondary outcome

  41. Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image

    Time frame: 5 years

    long-term secondary outcome

  42. Metabolite profiles in participants' faecal samples and serum samples

    Time frame: 6 months

    short-term secondary outcome: metabolite composition was analyzed via liquid chromatography tandem mass spectrometry (LC-MS/MS)

  43. Metabolite profiles in participants' faecal samples and serum samples

    Time frame: 2 years

    long-term secondary outcome: metabolite composition was analyzed via liquid chromatography tandem mass spectrometry (LC-MS/MS)

  44. Incidence of stroke event including ischemic and hemorrhagic stroke

    Time frame: 6 months

    short-term secondary outcome

  45. Incidence of stroke event including ischemic and hemorrhagic stroke

    Time frame: 2 years

    long-term secondary outcome

  46. Incidence of stroke event including ischemic and hemorrhagic stroke

    Time frame: 5 years

    long-term secondary outcome

  47. Change in the Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) diet scale (minimum value = 0, maximum value = 14, and higher scores mean a better outcome)

    Time frame: 6 months

    short-term secondary outcome

  48. Change in the Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND) diet scale (minimum value = 0, maximum value = 15, and higher scores mean a better outcome)

    Time frame: 6 months

    short-term secondary outcome

Study contacts

Contact information is provided by the study sponsor or research team.

Min Lou, PhD, MD

CONTACT

[email protected]

13958007213

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Registry information

Official study title

Oriental Intervention for Enhanced Neurocognitive Health (Orient) Diet in Populations With High Risk of Stroke (ENDS): a Randomized Controlled Trial

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Oct 24, 2023
Registry last updated
Jun 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.